Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis: Results of a randomized controlled clinical trial

Journal of Clinical Investigation

Volumn 102, Issue 8, 1998, Pages 1627-1633

  Lane, Nancy E ^a,b   Sanchez, Sarah ^a   Modin, Gunnar W ^a   Genant, Harry K ^a   Pierini, Elena ^a   Arnaud, Claude D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Corticosteroid induced osteoporosis; Parathyroid hormone treatment

Indexed keywords

CORTICOSTEROID; ESTROGEN; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34];

ADULT; AGED; ARTICLE; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOREARM; HIP; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; OSTEOLYSIS; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0032532062     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI3914     Document Type: Article

References (29)

1. Lukert, B.P., and L.G. Raisz. 1990. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann. Intern. Med. 112:352-364.
2. Adachi, J.D., W.G. Benson, and A.B. Hodsman. 1993. Corticosteroid-induced osteoporosis. Semin. Arthritis. Rheum. 23:375-384.
3. Dempster, D.W., M.A. Arlot, and P.J. Menuier. 1983. Mean wall thickness and formation periods of trabecular bone packets in corticosteroid-induced osteoporosis. Calcif. Tissue Int. 35:410-417.
4. Buckley, L.M., E.S. Leib, K.S. Cartularo, P.M. Vacek, and S.M. Cooper. 1996. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 125:961-968.
5. Hall, G.M., M. Daniels, D.V. Doyle, and T.D. Spector. 1994. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum. 37:1499-1505.
6. Adachi, J.D., W.G. Bensen, J. Brown, D. Hanley, A. Hodsman, R. Josse, D.L. Kendler, B. Lentle, W. Olszynski, L.G. Ste.-Marie, et al. 1997. Intermittent etidronate therapy to prevent corticosteroids-induced osteoporosis. N. Engl. J. Med. 337:382-387.
7. Sambrook, P., J. Birmingham, P. Kelly, et al. 1993. Prevention of corticosteroid osteoporosis: a comparison of calcium, calcitriol, and calcitonin. N. Engl. J. Med. 328:1747-1753.
8. Saag, K.G., R. Emkey, T. Schnitzer, J. Brown, F. Hawkins, S. Goemaere, G. Thamsborg, V. Lieberman, P. Delmas, M. Pierre-Malice, et al. 1998. Alendronate for the prevention of corticosteroid-induced osteoporosis: results of the combined United States and Multinational Studies. N. Engl. J. Med. 339:292-299.
9. Lindsay, R., J. Nieves, C. Formica, E. Henneman, L. Woelfert, V. Shen, D. Dempster, and F. Cosman. 1997. Randomised controlled study of the effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on estrogen with osteoporosis. Lancet. 350:550-555.
10. Reeve, J., J.N. Bradbeer, M. Arlot, et al. 1991. hPTH 1-34 treatment of osteoporosis with added hormone replacement therapy: biochemical, kinetic, and histological responses. Osteoporosis Int. 1:162-170.
11. Neer, R., D.M. Slovik, N. Daly, J.T. Potts, Jr., and S.R. Nussbaum. 1993. Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol. Osteoporosis Int. 1(Suppl.):204-205.
12. Slovik, D.M., D.I. Rosenthal, S.H. Doppelt, et al. 1986. Restoration of spinal bone in osteoporotic men by treatment with human parathyroid hormone (1-34) and 1,25 dihydroxyvitamim D.J. Bone Miner. Res. 1:377-381.
13. Genant, H.K., J.E. Block, P. Steiger, and C. Christian-Gluer. 1987. Quantitative computed tomography in the assessment of osteoporosis. Osteoporosis Update. H.K. Genant, editor. University of California Printing Services, San Francisco. 49-71.
14. Singer, F.R., J.P. Aldred, R.M. Neer, S.M. Krane, J.T. Potts, Jr., and K.F. Bloch. 1972. An evaluation of antibodies and clinical resistance to salmon calcitonin. J. Clin. Invest. 51:2331-2338.
15. Black, D.M., L. Palermo, M.C. Nevitt, H.K. Genant, R. Epstein, R. San Valentin, and S.R. Cummings. 1995. Comparison of methods for defining prevalent vertebral deformities: the study of osteoporotic fractures. J. Bone Miner. Res. 10:890-902.
16. Black, D.M., S.R. Cummings, D.B. Karpf, J.A. Cauley, D.E. Thompson, M.C. Nevitt, D. Bauer, H.K. Genant, W.L. Haskell, R. Marcus, et al. 1996. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 348:1535-1541.
17. Cummings, S.R., D.M. Black, M.C. Nevitt, W. Browner, J. Cauley, K. Ensrud, H.K. Genant, L. Palermo, J. Scott, and T.M. Vogt. 1993. Bone density al various sites for prediction of hip fractures. Lancet. 341:72-75.
18. Lane, N.E., J.M. Thompson, G.J. Strewler, and J.H. Kinney. 1995. Intermittent treatment with human parathyroid hormone (hPTH[1-34]) increased trabecular bone volume but not connectivity in osteopenic rats. J. Bone Miner. Res. 10:1470-1477.
19. Meng, X.W., X.G. Liang, R. Birchman, R.D.D. Wu, D.W. Dempster, R. Lindsay, and R.V. Shen. 1996. Temporal expression of the anabolic action of PTH in cancellous bone of ovariectomized rats. J. Bone Miner. Res. 11:421-429.
20. Mosekilde, L., C.C. Danielson, and J. Gasser. 1994. The effect on vertebral bone mass and strength of long-term treatment with anti-resorptive agents (estrogen and calcitonin). human parathyroid hormone-(1-38), and combination therapy, assessed in aged ovariectomized rats. Endocrinology. 134:2126-2134.
21. Sietsema, W.K. 1995. Animal models of cortical porosity. Bone. 17(4 Suppl.):297-305.
22. Brockstedt, H., P. Christiansen, L. Mosekilde, and F. Melsen. 1995. Reconstruction of cortical bone remodeling in untreated primary hyperparathy-roidism and following surgery. Bone. 16:109-117.
23. Guaydier-Souquieres, G., P.O. Kotzki, J.P. Sabatier, B. Basse-Cathalinat, and G. Loeb. 1996. In corticosteroid-treated respiratory diseases, monofluoro-phosphate increases lumbar bone density: a double-masked randomized study. Osteoporosis Int. 6:171-177.
24. Riggs, B.L., S.F. Hodgson, W.M. O'Fallon, E.Y.S. Chao, H.W. Wahner, J.M. Muhs, S.L. Cedely, and L.J. Melton. 1990. Effect of fluoride treatment on fracture rate in postmenopausal women with osteoporosis. N. Engl. J. Med. 322: 802-809.
25. Lukert, B.P., B.E. Johnson, and R.G. Robinson. 1992. Estrogen and progesterone replacement reduces glucocorticoid-induced bone loss. J. Bone Miner. Res. 7:1063-1069.
26. Neer, R., D. Slovik, M. Daly, C. Lo, J.T. Potts, Jr., and S. Nussbaum. 1990. Treatment of postmenopausal osteoporosis with daily parathyroid hormone plus calcitriol. In C. Christiansen, and K. Overgaard, editors. Osteoporosis. Third International Symposium on Osteoporosis. Osteopress ApS, Copenhagen. 1314-1317.
27. Tarn, C.S., J.N.M. Heersche, T.M. Murray, and J.A. Parsons. 1982. Parathyroid hormone stimulates bone apposition rate independently of its resorptive action: differential effects of intermittent and continuous administration. Endocrinology. 110:506-512.
28. Lee, K., J.D. Deeds, S. Chiba, M. Un-No, A.T. Bond, and G.V. Segre. 1994. Parathyroid hormone induces sequential c-fos expression in bone cells in vivo; in situ localization of its receptor and c-fos messenger ribonucleic acids. Endocrinology. 134:441-450.
29. Silve, C.M., G.T. Hradek, A.L, Jones, and C.D. Arnaud. 1982. Parathyroid hormone receptor in intact embryonic chick bone: characterization and cellular localization. J. Cell Biol. 94:379-386.